CN1662551A - 前列腺素e2受体亚型ep4的拮抗肽 - Google Patents

前列腺素e2受体亚型ep4的拮抗肽 Download PDF

Info

Publication number
CN1662551A
CN1662551A CN038146851A CN03814685A CN1662551A CN 1662551 A CN1662551 A CN 1662551A CN 038146851 A CN038146851 A CN 038146851A CN 03814685 A CN03814685 A CN 03814685A CN 1662551 A CN1662551 A CN 1662551A
Authority
CN
China
Prior art keywords
peptide
bip
pharmaceutical composition
receptor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038146851A
Other languages
English (en)
Chinese (zh)
Inventor
K·G·佩里
S·莫菲特
D·阿布兰
A·伯杰龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theratechnologies Inc
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of CN1662551A publication Critical patent/CN1662551A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN038146851A 2002-05-23 2003-05-23 前列腺素e2受体亚型ep4的拮抗肽 Pending CN1662551A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38233602P 2002-05-23 2002-05-23
US60/382,336 2002-05-23

Publications (1)

Publication Number Publication Date
CN1662551A true CN1662551A (zh) 2005-08-31

Family

ID=29584392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038146851A Pending CN1662551A (zh) 2002-05-23 2003-05-23 前列腺素e2受体亚型ep4的拮抗肽

Country Status (8)

Country Link
US (1) US20040023853A1 (enExample)
EP (1) EP1506220A1 (enExample)
JP (1) JP2006506327A (enExample)
CN (1) CN1662551A (enExample)
AU (1) AU2003233297A1 (enExample)
BR (1) BR0311247A (enExample)
CA (1) CA2485485A1 (enExample)
WO (1) WO2003099857A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101041687B (zh) * 2007-02-28 2010-09-29 长春博泰医药生物技术有限责任公司 Pge2特异结合的噬菌体环七肽及筛选方法和合成肽的用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565628A1 (en) * 2004-05-03 2005-11-10 Astellas Pharma Inc. The combination of prostaglandin e2 receptor antagonist and renin-angiotensin system inhibitor for treating renal diseases
US20060115785A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
CN101500504B (zh) * 2006-06-06 2012-06-13 雷卡奥索技术公司 转导正畸矫正装置
WO2010087425A1 (ja) 2009-01-30 2010-08-05 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
ES2537017T3 (es) 2010-09-29 2015-06-01 Nb Health Laboratory Co. Ltd. Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano
CN105431416B (zh) 2013-06-12 2019-01-08 科研制药株式会社 4-炔基咪唑衍生物和含有其作为有效成分的药物
TW201623277A (zh) * 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US10279044B2 (en) 2015-05-29 2019-05-07 Purdue Research Foundation Bone fracture repair by targeting of agents that promote bone healing
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
US20260191823A1 (en) * 2022-11-21 2026-07-09 Kyowa Hakko Bio Co., Ltd. Prophylactic or therapeutic agent for acute kidney injury induced by anticancer agent
WO2025115623A1 (ja) * 2023-11-28 2025-06-05 新田ゼラチン株式会社 プロスタグランジンｅ２産生抑制剤、それを含む飲食品、プロスタグランジンｅ２産生抑制方法、およびプロスタグランジンｅ２産生抑制剤の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
WO2001042281A1 (en) * 1999-12-06 2001-06-14 Hôpital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101041687B (zh) * 2007-02-28 2010-09-29 长春博泰医药生物技术有限责任公司 Pge2特异结合的噬菌体环七肽及筛选方法和合成肽的用途

Also Published As

Publication number Publication date
EP1506220A1 (en) 2005-02-16
CA2485485A1 (en) 2003-12-04
AU2003233297A2 (en) 2003-12-12
WO2003099857B1 (en) 2004-02-19
BR0311247A (pt) 2005-03-15
US20040023853A1 (en) 2004-02-05
WO2003099857A1 (en) 2003-12-04
JP2006506327A (ja) 2006-02-23
AU2003233297A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
JP7819087B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
TWI489992B (zh) 醯胺系胰高血糖素超級家族之胜肽前驅藥物
CN107206254A (zh) 白细胞介素‑23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CN1362968A (zh) 新的肽
KR20250043599A (ko) α4β7 인테그린 티오에테르 펩티드 길항제
CN105579467A (zh) 用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
US20040023853A1 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP6633523B2 (ja) Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
JP2006506327A5 (enExample)
CN112041330A (zh) 坎普他汀类似物及其医学用途
CA2954607C (en) Antagonists of neurokinin b in fish reproduction
AU2016354478A1 (en) Protease-activated receptor-2 modulators
CN110691788A (zh) 长效gip肽类似物
AU2003236751B2 (en) Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2alpha receptor
CN1057118C (zh) 重组的c140受体
EP1244693B1 (en) Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
CN102276698B (zh) 一种mc4-r环肽类激动剂及其用途
CN1443195A (zh) 新型lhrh拮抗剂,其制备方法和药物用途
TW202115101A (zh) Cd38結合劑及其用途
US20050164949A1 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
TW202321274A (zh) 人類運鐵蛋白受體結合肽
EP1878741A2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
HK40120544A (en) Cd38-binding agents and uses thereof
TW202602903A (zh) 肽、肽複合物、醫藥組成物、細胞培養用組成物以及用於醫療用、診斷用或研究用的組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication